Viking's Post-Hip Fracture Drug Succeeds In Phase II, But Pivotal Endpoints Unclear
Executive Summary
The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?